Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 125


Infliximab-Related Infusion Reactions Systematic Review.

Lichtenstein L, Ron Y, Kivity S, Ben-Horin S, Israeli E, Fraser GM, Dotan I, Chowers Y, Confino-Cohen R, Weiss B.

J Crohns Colitis. 2015 Jun 19. pii: jjv096. [Epub ahead of print]


Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal.

Ben-Horin S, Chowers Y, Ungar B, Kopylov U, Loebstein R, Weiss B, Eliakim R, Del Tedesco E, Paul S, Roblin X.

Aliment Pharmacol Ther. 2015 Jun 1. doi: 10.1111/apt.13268. [Epub ahead of print]


Ashkenazi jewish origin protects against formation of antibodies to infliximab and therapy failure.

Ungar B, Haj-Natour O, Kopylov U, Yavzori M, Fudim E, Picard O, Loebstein R, Lahat A, Maor Y, Avidan B, Lang A, Weiss B, Chowers Y, Eliakim R, Ben-Horin S.

Medicine (Baltimore). 2015 May;94(18):e673. doi: 10.1097/MD.0000000000000673.


Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima.

Ben-Horin S, Yavzori M, Benhar I, Fudim E, Picard O, Ungar B, Lee S, Kim S, Eliakim R, Chowers Y.

Gut. 2015 Apr 20. pii: gutjnl-2015-309290. doi: 10.1136/gutjnl-2015-309290. [Epub ahead of print]


Rac1 Polymorphisms and Thiopurine Efficacy in Children with Inflammatory Bowel Disease.

Lev-Tzion R, Renbaum P, Beeri R, Ledder O, Mevorach R, Karban A, Koifman E, Efrati E, Muise AM, Chowers Y, Turner D.

J Pediatr Gastroenterol Nutr. 2015 Apr 10. [Epub ahead of print]


Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: Results of double blind Phase II clinical trial.

Israeli E, Goldin E, Fishman S, Konikoff F, Lavy A, Chowers Y, Melzer E, Lahat A, Mahamid M, Shirin H, Nussinson E, Segol O, Ya'acov AB, Shabbat Y, Ilan Y.

Clin Exp Immunol. 2015 Apr 4. doi: 10.1111/cei.12640. [Epub ahead of print]


Significance of low level infliximab in the absence of anti-infliximab antibodies.

Ungar B, Anafy A, Yanai H, Ron Y, Yavzori M, Picard O, Fudim E, Loebstein R, Kopylov U, Chowers Y, Dotan I, Eliakim R, Ben-Horin S.

World J Gastroenterol. 2015 Feb 14;21(6):1907-14. doi: 10.3748/wjg.v21.i6.1907.


Accuracy of capsule colonoscopy in detecting colorectal polyps in a screening population.

Rex DK, Adler SN, Aisenberg J, Burch WC Jr, Carretero C, Chowers Y, Fein SA, Fern SE, Fernandez-Urien Sainz I, Fich A, Gal E, Horlander JC Sr, Isaacs KL, Kariv R, Lahat A, Leung WK, Malik PR, Morgan D, Papageorgiou N, Romeo DP, Shah SS, Waterman M.

Gastroenterology. 2015 May;148(5):948-957.e2. doi: 10.1053/j.gastro.2015.01.025. Epub 2015 Jan 22.


Prognosis of primary sclerosing cholangitis in israel is independent of coexisting inflammatory bowel Disease.

Yanai H, Matalon S, Rosenblatt A, Awadie H, Berdichevski T, Snir Y, Kopylov U, Katz L, Stein A, Mlynarsky L, Tulchinsky H, Konikoff FM, Horin SB, Braun M, Ben-Ari Z, Chowers Y, Baruch Y, Shibolet O, Dotan I.

J Crohns Colitis. 2015 Feb;9(2):177-84.


[Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis (Spanish version)].

Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire S, Travis S, Lindsay JO, van Assche G.

Rev Gastroenterol Mex. 2014 Oct-Dec;79(4):263-89. doi: 10.1016/j.rgmx.2014.10.001. Epub 2014 Dec 6. Spanish. No abstract available.


Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease.

Pariente B, Mary JY, Danese S, Chowers Y, De Cruz P, D'Haens G, Loftus EV Jr, Louis E, Panés J, Schölmerich J, Schreiber S, Vecchi M, Branche J, Bruining D, Fiorino G, Herzog M, Kamm MA, Klein A, Lewin M, Meunier P, Ordas I, Strauch U, Tontini GE, Zagdanski AM, Bonifacio C, Rimola J, Nachury M, Leroy C, Sandborn W, Colombel JF, Cosnes J.

Gastroenterology. 2015 Jan;148(1):52-63.e3. doi: 10.1053/j.gastro.2014.09.015. Epub 2014 Sep 21.


Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.

Yanai H, Lichtenstein L, Assa A, Mazor Y, Weiss B, Levine A, Ron Y, Kopylov U, Bujanover Y, Rosenbach Y, Ungar B, Eliakim R, Chowers Y, Shamir R, Fraser G, Dotan I, Ben-Horin S.

Clin Gastroenterol Hepatol. 2015 Mar;13(3):522-530.e2. doi: 10.1016/j.cgh.2014.07.029. Epub 2014 Jul 25.


Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease.

Mazor Y, Almog R, Kopylov U, Ben Hur D, Blatt A, Dahan A, Waterman M, Ben-Horin S, Chowers Y.

Aliment Pharmacol Ther. 2014 Sep;40(6):620-8. doi: 10.1111/apt.12869. Epub 2014 Jul 15.


Expression of IL-2, IL-17 and TNF-alpha in patients with Crohn's disease treated with anti-TNF antibodies.

Katz LH, Kopylov U, Fudim E, Yavzori M, Picard O, Ungar B, Eliakim R, Ben-Horin S, Chowers Y.

Clin Res Hepatol Gastroenterol. 2014 Sep;38(4):491-8. doi: 10.1016/j.clinre.2014.01.010. Epub 2014 Mar 5.


Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.

Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, Cottone M, de Ridder L, Doherty G, Ehehalt R, Esteve M, Katsanos K, Lees CW, Macmahon E, Moreels T, Reinisch W, Tilg H, Tremblay L, Veereman-Wauters G, Viget N, Yazdanpanah Y, Eliakim R, Colombel JF; European Crohn's and Colitis Organisation (ECCO).

J Crohns Colitis. 2014 Jun;8(6):443-68. doi: 10.1016/j.crohns.2013.12.013. Epub 2014 Mar 6. No abstract available.


Letter: European Medicines Agency recommendations for allergic reactions to intravenous iron-containing medicines.

Gomollón F, Chowers Y, Danese S, Dignass A, Haagen Nielsen O, Lakatos PL, Lees CW, Lindgren S, Lukas M, Mantzaris GJ, Michetti P, Moum B, Peyrin-Biroulet L, Toruner M, van der Woude J, Weiss G, Stoevelaar H, Reinisch W.

Aliment Pharmacol Ther. 2014 Apr;39(7):743-4. doi: 10.1111/apt.12648. No abstract available.


Tailoring anti-TNF therapy in IBD: drug levels and disease activity.

Ben-Horin S, Chowers Y.

Nat Rev Gastroenterol Hepatol. 2014 Apr;11(4):243-55. doi: 10.1038/nrgastro.2013.253. Epub 2014 Jan 7. Review.


Recurrent small intestinal ileus secondary to valsartan treatment.

Saadi T, Brun R, Chowers Y, Baruch Y, Waterman M.

J Clin Gastroenterol. 2014 May-Jun;48(5):462-3. doi: 10.1097/MCG.0000000000000045. No abstract available.


Celiac disease resolution after allogeneic bone marrow transplantation is associated with absence of gliadin-specific memory response by donor-derived intestinal T-cells.

Ben-Horin S, Polak-Charcon S, Barshack I, Picard O, Fudim E, Yavzori M, Avivi C, Mardoukh C, Shimoni A, Chowers Y, Maor Y.

J Clin Immunol. 2013 Nov;33(8):1395-402. doi: 10.1007/s10875-013-9943-9. Epub 2013 Oct 20.


The management of iron deficiency in inflammatory bowel disease--an online tool developed by the RAND/UCLA appropriateness method.

Reinisch W, Chowers Y, Danese S, Dignass A, Gomollón F, Nielsen OH, Lakatos PL, Lees CW, Lindgren S, Lukas M, Mantzaris GJ, Michetti P, Moum B, Peyrin-Biroulet L, Toruner M, van der Woude J, Weiss G, Stoevelaar H.

Aliment Pharmacol Ther. 2013 Nov;38(9):1109-18. doi: 10.1111/apt.12493. Epub 2013 Sep 17.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk